Jawad Bhatti, MD
Internal Medicine · Richmond, VANPI 1609912351
Payments from drug & device makers
Across 261 payments — averaging $39.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- International Rehabilitative Sciences, Inc$4K
- Collegium Pharmaceutical, Inc.$1K
- Hikma Pharmaceuticals USA$485
- AbbVie$440
- Purdue Pharma L.p.$414
- Pfizer$410
- plus $3K from 29 others
What the payments were for
- Consulting fees$240%
- Food & beverage$4,67652%
- Education$210%
- Other$4,28848%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| International Rehabilitative Sciences, Inc | 2 | $4,316 |
| Collegium Pharmaceutical, Inc. | 101 | $1,316 |
| Hikma Pharmaceuticals USA | 5 | $485 |
| AbbVie(2 entities) | 27 | $440 |
| Purdue Pharma L.p. | 1 | $414 |
| Pfizer | 18 | $410 |
| Endo Pharmaceuticals Inc. | 1 | $376 |
| Biodelivery Sciences International, Inc. | 21 | $321 |
| Medtronic | 2 | $261 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $251 |
| Biohaven Pharmaceuticals, Inc. | 9 | $189 |
| AstraZeneca | 4 | $134 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Seagen Inc. | 1 | $125 |
| Pharming Healthcare, Inc. | 1 | $125 |
| Novartis | 1 | $102 |
| Eisai Inc. | 5 | $100 |
| MDD US Operations, LLC | 5 | $86 |
| Bausch Health US, LLC | 4 | $79 |
| Vertex | 4 | $73 |
| Indivior Inc. | 5 | $68 |
| Redhill Biopharma Inc. | 4 | $64 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $57 |
| Scilex Pharmaceuticals Inc. | 3 | $47 |
| Assertio Therapeutics, Inc. | 3 | $46 |
| Nevro Corp. | 1 | $31 |
| Merck | 2 | $29 |
| Kaleo, Inc. | 2 | $28 |
| Orexo US, Inc. | 1 | $22 |
| Medline Industries LP | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Zyla Life Sciences, Inc. | 1 | $13 |
| Almatica Pharma LLC | 1 | $13 |
| Shionogi Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RS-4i Plus with Intersperse$4,288
- RS-FBG RS-LBG$4,288
- ClosureFast$261
- PADCEV$125
- LIBTAYO$125
- JOENJA$125
- ADAKVEO$102
How this compares
$10,213 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 20 | $51,396 |
| BelbucaBuprenorphine Hcl | 56 | $39,803 |
| Xtampza ErOxycodone Myristate | 83 | $37,857 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 240 | $33,585 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 618 | $21,233 |
| Oxycodone Hcl | 975 | $21,142 |
| Buprenorphine | 63 | $17,018 |
| LinzessLinaclotide | 13 | $10,080 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 363 | $9,869 |
| Morphine Sulfate ErMorphine Sulfate | 426 | $9,191 |
| Lidocaine | 44 | $7,528 |
| OxycontinOxycodone Hcl | 11 | $6,308 |
| Butorphanol Tartrate | 28 | $5,478 |
| Hydromorphone Hcl | 294 | $4,427 |
| Naloxone Hcl | 62 | $4,083 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $1,316 | $77,660139 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine, Buprenorphine Hcl, Morphine Sulfate | $485 | $54,988490 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $251 | $51,39620 claims |
| AbbVieLinzess | $440 | $10,08013 claims |
| Purdue Pharma L.p.Oxycontin | $414 | $6,30811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Richmond
- Leroy VaughanRichmond$20.8M
- Andrew PoklepovicRichmond$4.6M
- Richard JacksonRichmond$2.5M
- Lawrence SchwartzRichmond$2.4M
- John HoekstraRichmond$344K
- Franklin ZieveRichmond$337K
- Wally SmithRichmond$333K
- Thokozeni LipatoRichmond$247K
- John BarrettRichmond$217K
- Alan DowRichmond$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.